Tag: Biotech and Pharma

GSK (GSK) reported higher earnings on increased specialty medicine sales and said it expects to pay a total dividend this year of 70 pence a share.

AstraZeneca (AZN)  beat first-quarter profit expectations and maintained its 2026 forecasts on Wednesday, supported by strong demand for its cancer and rare-disease drugs and investments in the key U.S. and China markets.

Novartis (NOVN) reported a drop in earnings as generic competition for its top-selling heart drug Entresto hit sales in the first months of the year.

Την Ετήσια Ενημέρωση Αναλυτών πραγματοποίησε σήμερα η Lavipharm A.E. σύμφωνα με το Οικονομικό Ημερολόγιο 2026 της Εταιρείας. Η παρουσίαση πραγματοποιήθηκε στο Χρηματιστήριο Αθηνών, στην Ένωση Θεσμικών Επενδυτών.

 Eli Lilly (LLY) said on Monday ‌it would buy privately held blood cancer treatment developer Ajax Therapeutics for up to $2.3 ​billion in cash.

Sanofi (SASY) beat first-quarter estimates on Thursday as demand for ‌its asthma and eczema drug Dupixent remained high, though analysts looked to incoming CEO Belén Garijo to ignite growth beyond the blockbuster drug.

Roche reported falling sales in the first three months of the year, as the strength of the Swiss franc and generic competition for some of its older drugs weighed on the drugmaker.

U.S. drugmaker Eli Lilly (LLY) is in advanced talks to acquire ​biotech firm Kelonia Therapeutics for more than $2 ‌billion, the Wall Street Journal reported on Sunday.

Abbott Laboratories reported first-quarter earnings in line with expectations and revenue above forecasts on Wednesday, but shares slipped after the medical device maker issued soft second-quarter profit guidance.

Novo Nordisk is partnering with OpenAI to “bring new and better treatment options to patients faster,” the Danish drugmaker said Tuesday.

Johnson & Johnson (JNJ) has reinvented itself several times in recent years. In 2021, it was best known as the developer of a Covid vaccine.

Σε συμφωνία με την Janssen Global Services ήρθε η Lavipharm A.E. για την απόκτηση των δικαιωμάτων του συνταγογραφούμενου διαδερμικού επιθέματος DUROGESIC

Revolution Medicines’ drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy, the company said Monday.

After years of trying to lose weight “the right way,” Jane Zuckerman realized that “putting in the work just wasn’t enough.”

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street.

Novo Nordisk rose as much as 4% after England’s drug price watchdog recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes, marking the first GLP-1 backed for this use in the country.

Eli Lilly has agreed to buy clinical-stage company Centessa Pharmaceuticals for an initial payment of about $6.3 billion in a deal that expands the drugmaker’s neuroscience portfolio and capabilities into sleep medicine.

Novo Nordisk will launch a discounted subscription plan for U.S. Wegovy patients paying for the drug themselves, offering monthly ‌prices up to nearly 30% below its standard rate as it tries to widen access and regain ground from Eli Lilly in the booming obesity-drug market.

Novartis is planning to buy U.S.-based biotech Excellergy for up to $2 billion, betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.

Merck to pay a 6% premium to buy the outstanding shares of Terns Pharmaceuticals, which is developing an oral treatment for leukemia.